Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Mental Illness Clear all
Not listed Not applicable Interventional

Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT

NCT02120729
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Genotype-guided care
Other
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT02153502
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Not applicable Interventional

The Effects of the Be Mindful Intervention in Previously Depressed Individuals Experiencing Subclinical Symptoms

NCT04740879
View directory record Official record
Conditions
Depressive Symptoms, Major Depressive Disorder, Recurrent, in Remission
Interventions
Be Mindful
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Not applicable Interventional

Triple Chronotherapy in Adolescents

NCT03679962
View directory record Official record
Conditions
Depressive Disorder, Major, Bipolar Depression, Suicidal Ideation
Interventions
Triple Chronotherapy, Treatment as Usual
Behavioral
Lead sponsor
Billings Clinic
Other
Eligibility
12 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Billings, Montana
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 17, 2026, 5:21 AM EDT
Not yet recruiting Not applicable Interventional

EEG-Guided Transcranial Magnetic Stimulation for Adults With Depression

NCT07862205
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Treatment Resistant Depression, Major Depression
Interventions
MagVenture TMS Therapy System with Localite Navigation System and actiCHamp EEG
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
22 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 5:21 AM EDT
Recruiting No phase listed Observational

Maternal And Infant Antipsychotic Study

NCT06049953
View directory record Official record
Conditions
Antipsychotics, Pregnancy
Interventions
Antipsychotics, Non-antipsychotic medication, No Medication
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Phase 3 Interventional

African American Depression Intervention Trial (AADI)

NCT01342536
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
30 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 17, 2026, 5:21 AM EDT
Recruiting No phase listed Observational

Congenital Muscle Disease Study of Patient and Family Reported Medical Information

NCT01403402
View directory record Official record
Conditions
Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan and Epilepsy), Alpha-Dystroglycanopathy (Dystroglycanopathy, Congenital With or Without Mental Retardation (Formerly MDC1C)), Alpha-Dystroglycanopathy (Fukuyama CMD), Alpha-Dystroglycanopathy (LGMDR09 FKRP Related (Formerly LGMD2I)), Alpha-Dystroglycanopathy (LGMDR11 POMT1 Related (Formerly LGMD2K)), Alpha-Dystroglycanopathy (LGMDR13 FKTN Related (Formerly LGMD2M)), Alpha-Dystroglycanopathy (LGMDR14 POMT2 Related (Formerly LGMD2N)), Alpha-Dystroglycanopathy (LGMDR15 POMGnT1 Related (Formerly LGMD2O)), Alpha-Dystroglycanopathy (LGMDR19 GMPPB Related (Formerly LGMD2T)), Alpha-Dystroglycanopathy (LGMDR20 ISPD Related (Formerly LGMD2U)), Alpha-Dystroglycanopathy (LGMDR24 POMGnT2 Related), Alpha-Dystroglycanopathy (Muscle Eye Brain Disease (MEB)), Alpha-Dystroglycanopathy (Walker Warburg Syndrome (WWS)), Choline Kinase B Receptor - CHKB, Collagen VI Related Disorders, Collagen XII Related Disorders, Congenital Muscular Dystrophy Not Otherwise Specified (Including Merosin Positive), Congenital Muscular Dystrophy With Cataracts and Intellectual Disability (MDCCAID), Congenital Muscular Dystrophy With Joint Hyperlaxity, Congenital Muscular Dystrophy With Rigid Spine Related to ACTA1, Emery-Dreifuss Muscular Dystrophy, GOLGA2-related Congenital Muscle Dystrophy With Brain Involvement, LMNA Related Disorders, Merosin Deficient CMD (Full or Partial), Nesprin Related MD (SYNE1), SELENON Related Disorders (Previously Known as SEPN1), SELENON Related Myopathy (Aka SEPN1), Telethonin CMD, Congenital Myasthenic Syndrome, Limb-Girdle Muscular Dystrophy, LGMDD01 - DNAJB6 (Formerly LGMD1D), LGMDD05 - Collagen VI Related Bethlem Myopathy (Dominant), LGMDR07 - Telethonin (TCAP) Related (Formerly LGMD2G), LGMDR08 - TRIM Related (Formerly LGMD2H), LGMDR09 - FKRP Related (Formerly LGMD2I), LGMDR10 - Titin (TTN) Related (Formerly LGMD2J), LGMDR11 - POMT1 Related (Formerly LGMD2K), LGMDR13 - Fukutin (FKTN) Related (Formerly LGMD2M), LGMDR14 - POMT2 Related (Formerly LGMD2N), LGMDR15 - POMGnT1 Related (Formerly LGMD2O), LGMDR16 - DAG1 Related Dystroglycanopathy (Formerly LGMD2P), LGMDR17 - Plectin (PLEC) Related (Formerly LGMD2Q), LGMDR18 - TRAPPC11 Related (Formerly LGMD2S), LGMDR19 - GMPPB Related (Formerly LGMD2T), LGMDR20 - ISPD Related (Formerly LGMD2U), LGMDR22 - Collagen VI Related Bethlem Myopathy (Recessive), LGMDR23 - LAMA2 Related, LGMDR24 - POMGnT2 Related
Interventions
Not listed
Lead sponsor
Cure CMD
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Not applicable Interventional

Trial of a Positive Psychology Intervention in Major Depressive Disorder

NCT02004145
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Positive Psychology, Control Condition
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Not applicable Interventional

Sounds for Sleep Study in Patients Suffering From Moderate to Severe Insomnia

NCT06021795
View directory record Official record
Conditions
Insomnia
Interventions
Sound Treatment
Device
Lead sponsor
Third Wave Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 17, 2026, 5:21 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder

NCT00659347
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DOV 21, 947, Placebo
Drug
Lead sponsor
DOV Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
10
States / cities
Norwich, Connecticut • Springfield, Massachusetts • Cherry Hill, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2008 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Individualizing Incentives for Alcohol in the Severely Mentally Ill

NCT03481049
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Alcohol Dependence
Interventions
Usual CM, High-Magnitude CM, Shaping CM
Behavioral
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
2
States / cities
Seattle, Washington • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Phase 4 Interventional

Comparing Various Treatments for Achieving and Maintaining Remission of Depression

NCT00227955
View directory record Official record
Conditions
Depression
Interventions
Imipramine, Interpersonal Psychotherapy
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 1993
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Focal Electroconvulsive Therapy for Depression

NCT01589315
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
focal ECT
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

NCT00969150
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
25
States / cities
Scottsdale, Arizona • Encino, California • Los Alamitos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 17, 2026, 5:21 AM EDT
Terminated Phase 4 Interventional Results available

Lexapro for Major Depression in Patients With Epilepsy

NCT01244724
View directory record Official record
Conditions
Major Depression, Epilepsy
Interventions
Lexapro
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 17, 2026, 5:21 AM EDT
Recruiting Phase 3 Interventional

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT05850689
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
25
States / cities
Huntsville, Alabama • Pico Rivera, California • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group

NCT00265291
View directory record Official record
Conditions
Major Depressive Disorder, Major Depression, Unipolar Depression
Interventions
fluoxetine or desipramine
Drug
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2008 · Synced Oct 17, 2026, 5:21 AM EDT
Not yet recruiting Early Phase 1 Interventional

Individualized fMRI-guided TMS for Depression

NCT07804459
View directory record Official record
Conditions
Depression, Major Depressive Disorder (MDD), Depression - Major Depressive Disorder, Persistent Depressive Disorder, PDD, MDD
Interventions
Active Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression

NCT00699218
View directory record Official record
Conditions
Mood Disorder, Bipolar Disorder, Major Depression, Depression
Interventions
Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 17, 2026, 5:21 AM EDT
Not yet recruiting Not applicable Interventional

Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support

NCT07073924
View directory record Official record
Conditions
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Interventions
Implementation strategy bundle
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 17, 2026, 5:21 AM EDT
Completed No phase listed Observational

Neurocardiac Control in Major Depression

NCT00084162
View directory record Official record
Conditions
Depression, Involutional
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

NCT01204918
View directory record Official record
Conditions
Depression
Interventions
Riluzole, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 17, 2026, 5:21 AM EDT
Not yet recruiting Not applicable Interventional

Prediction and Prevention of Postoperative Mortality and Morbidity

NCT06042413
View directory record Official record
Conditions
Dementia, Postoperative Delirium (POD), Postoperative Neurocognitive Disorder, Major Adverse Cardiac and Cerebrovascular Events, Perioperative Complications, Postoperative Cognitive Decline
Interventions
Personalized CPC Prehabilitation, Cognitive Training, Meditation, Daily Exercise, Enhanced Social Support, Proactive Bundle Interventions, Pre-operative Standard of Care, Intra-operative Standard of Care
Other · Behavioral · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 5:21 AM EDT